In recent years, mRNA in lipid nanoparticles (mRNA–LNPs) has emerged as a promising strategy for treating numerous conditions ...

About four years after the case was filed—and against the backdrop of a significantly changed COVID-19 vaccine landscape—Moderna has resolved a long-running patent feud. | Moderna will pay $950 ...

Moderna will pay US$950-million upfront in July, 2026, with an additional US$1.3-billion contingent on the outcome of a separate legal appeal, while not owing royalties for the technology in its ...

Transaction is Hopewell’s first commercial license of proprietary lipid nanoparticles (LNPs)Hopewell’s LNPs are the preferred delivery solution ...

Expands Pfizer’s access to lipid nanoparticle (LNP) formulation technology, offering a strong strategic fit with Pfizer’s mRNA strategy Pfizer gains option to license Acuitas’ LNP technology for up to ...

Vaccines and other medicines are often packed in little fat droplets, or lipids. In this form, they are absorbed by cells and release their “cargo” once they are there. The trigger is a change in the ...

The settlement, which requires Moderna to pay the plaintiffs $950 million upfront plus up to $1.3 billion in contingent commitments, is an outcome “better than feared,” according to analysts.

Moderna (NASDAQ:MRNA) has agreed to pay US$950 million to resolve a long-running patent dispute tied to the technology used ...

Lipid nanoparticles deliver mRNA to insulin-producing beta cells, prompting them to express a protective protein that shields them from autoimmune attack.

Partner Dan Shores will present a webinar titled "The mRNA/Lipid Nanoparticle Competitive and Litigation Landscape" for Medmarc, the leading expert in the products liability risks facing medical ...

Hopewell Therapeutics sublicenses its proprietary lipid nanoparticles for novel cancer vaccine to Foxcroft Therapeutics: Woburn, Massachusetts Saturday, March 7, 2026, 17:00 Hrs [ ...